Project description
Bioactive nanocarriers as an oral peptide delivery strategy
Development of a novel oral drug delivery system for therapeutic peptides is a major challenge in the treatment of chronic diseases such as type 2 diabetes. This EU-funded project will work on the application of nanocarriers for peptide delivery, which protects its cargo against chemical and enzymatic degradation while enabling controlled release, targeting and increased bio-availability. Project strategy stems from an earlier observation that lipid-based nanocarriers themselves trigger endogenous bio-active peptide secretion in vivo after oral administration to mice. Current research will aim to develop a dual-action delivery system that combines the biological effect of the nanocarriers and that of the encapsulated drug to enable complex and very efficient treatments for gastrointestinal disorders.
Objective
The development of new oral drug delivery systems that will enable the absorption of therapeutic peptides to the systemic circulation is one of the greatest current challenges for the pharmaceutical industry and is the ‘holy grail’ of peptide delivery. Improved novel drug delivery systems are of utmost importance in order to fulfill the potential of this route of administration in the treatment of chronic diseases (e.g. type 2 diabetes mellitus), where daily injections are often required.
There are various advantages of using nanocarriers for this purpose: they offer protection against chemical and enzymatic degradation, controlled release, targeting, tolerability and/or improved uptake and translocation resulting in enhanced bioavailability and greater therapeutic efficacy. I was the first to demonstrate that lipid-based nanocarriers trigger endogenous glucagon-like peptide (GLP)-1 and GLP-2 secretion in vivo after orally administered to mice. This effect can be exploited to develop a novel and unconventional drug delivery nanosystem as a promising strategy for the treatment of gastrointestinal disorders (e.g. type 2 diabetes mellitus, Crohn’s disease, ulcerative colitis).
There are significant gaps in current knowledge that need to be addressed to make this possible. I propose a series of studies to answer the following key questions: -First, can we develop a dual-action drug delivery nanosystem that synergizes its own biological effect and that of the encapsulated bioactive molecule? -Second, can we ameliorate type 2 diabetes mellitus (T2DM) and inflammatory bowel diseases (IBD) using an oral peptide-loaded dual-action lipid-based nanosystem? –Third, is this innovative strategy a viable alternative to current treatments in T2DM and IBD? By exploiting the gut pathophysiology, I propose an innovative therapeutic approach using cutting-edge advanced technologies to deal with an unmet therapeutical need in the treatment of gastrointestinal disorders.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine physiology pathophysiology
- natural sciences biological sciences biochemistry biomolecules
- medical and health sciences clinical medicine endocrinology diabetes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-STG - Starting Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2019-STG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1348 LOUVAIN LA NEUVE
Belgium
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.